Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
5 Results for "
SV-HUC-1
" in MedChemExpress (MCE) Product Catalog:
Products (5)
5 Results for "SV-HUC-1" in MCE Product Catalog:
1
1 Cited Publications
Target:
Research Areas:
NVS-CECR2-1, a non-BET family Bromodomain (BRD) inhibitor, is a potent and selective cat eye syndrome chromosome region, candidate 2 (CECR2) inhibitor. NVS-CECR2-1 binds to CECR2 BRD with high affinity (IC50=47 nM; KD=80 nM). NVS-CECR2-1 exhibits cytotoxic activity and induces apoptosis against various cancer cells by targeting CECR2 as well as via CECR2-independent mechanism [1]. NVS-CECR2-1 is a chemical probe.
Cat. No.: HY-174086
CAS No.: 3071165-43-7
Research Areas:
PROTAC GPX4 degrader-4 is a potent GPX4 PROTAC degrader, with DC50 values of 1366.67 nM and 475.15 nM in T24 and RT4 cells, respectively. PROTAC GPX4 degrader-4 targets and degrades GPX4 protein via the ubiquitin-proteasome system, thereby inducing cellular ferroptosis. PROTAC GPX4 degrader-4 can be used for research on bladder cancer [1].
Cat. No.: HY-183312
Research Areas:
Antitumor agent-217 is a dual mitochondria-targeted anticancer agent. Antitumor agent-217 exhibits potent and selective antiproliferative activity against bladder cancer cell line J82 (IC50 = 6.3 μM), and inhibits colony formation and migration of J82 cells. Antitumor agent-217 accumulates in mitochondria, alters mitochondrial morphology, reduces ATP production, increases ROS generation and decreases mitochondrial membrane potential. Antitumor agent-217 induces apoptosis (Apoptosis) and ferroptosis (Ferroptosis) in bladder cancer cells. Antitumor agent-217 can be used for the research of bladder cancer [1].
Cat. No.: HY-183297
CDK4-IN-5 is a potent, orally active and selective CDK4 inhibitor. CDK4-IN-5 suppresses CDK4 expression and downregulates the CDK4/CyclinD1 complex. CDK4-IN-5 induces G0/G1 phase cell cycle arrest in bladder cancer cells via CyclinD1 expression suppression. CDK4-IN-5 selectively exerts activity against bladder cancer cells. CDK4-IN-5 can be used for the research of bladder cancer [1].
Cat. No.: HY-110374R
CAS No.: 1992047-61-6
Research Areas:
NVS-CECR2-1 (Standard) is the analytical standard of NVS-CECR2-1 (HY-110374). This product is intended for research and analytical applications. NVS-CECR2-1, a non-BET family Bromodomain (BRD) inhibitor, is a potent and selective cat eye syndrome chromosome region, candidate 2 (CECR2) inhibitor. NVS-CECR2-1 binds to CECR2 BRD with high affinity (IC50=47 nM; Kd=80 nM). NVS-CECR2-1 exhibits cytotoxic activity and induces apoptosis against various cancer cells by targeting CECR2 as well as via CECR2-independent mechanism [1]. NVS-CECR2-1 is a chemical probe.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
